PUBLIC COMPANY
save$MLYSMineralys Therapeutics, Inc.
$MLYS26.05+1.60%Radnor, PA, USupdated 1h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
- phase2A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- phase2A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
- phase3Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
- phase2Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
- phase2Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 17, 26SELLRodman David Malcom· Chief Medical Officer−$13K↗
- Apr 15, 26SELLRodman David Malcom· Chief Medical Officer−$176K↗
- Apr 13, 26SELLCongleton Jon· Chief Executive Officer−$422K↗
- Apr 13, 26SELLRodman David Malcom· Chief Medical Officer−$373K↗
- Apr 9, 26SELLRodman David Malcom· Chief Medical Officer−$59K↗
- Mar 31, 26SELLCongleton Jon· Chief Executive Officer−$1.46M↗
- Mar 31, 26SELLCongleton Jon· Chief Executive Officer−$494K↗
- Mar 31, 26SELLKarydas Daphne· director−$75K↗
- Mar 31, 26SELLCongleton Jon· Chief Executive Officer−$12K↗
- Mar 30, 26BUYRA CAPITAL MANAGEMENT, L.P.· $1.41M↗
- Mar 27, 26BUYRA CAPITAL MANAGEMENT, L.P.· $7.35M↗
- Mar 17, 26SELLRodman David Malcom· Chief Medical Officer−$11K↗
- Mar 13, 26SELLRodman David Malcom· Chief Medical Officer−$278K↗
- Mar 13, 26SELLRodman David Malcom· Chief Medical Officer−$84K↗
- Mar 13, 26SELLRodman David Malcom· Chief Medical Officer−$7K↗
- Mar 12, 26SELLRodman David Malcom· Chief Medical Officer−$174K↗
- Mar 9, 26SELLRodman David Malcom· Chief Medical Officer−$58K↗
routine RSU / option mechanics (3)
- Apr 17, 26option exerciseRodman David Malcom · Chief Medical Officer416 sh
- Apr 17, 26option exerciseRodman David Malcom · Chief Medical Officer416 sh
- Apr 13, 26option exerciseRodman David Malcom · Chief Medical Officer4,167 sh
🐶 Hiring Signal
News
- FDA approves AstraZeneca’s new kind of hypertension drugBaxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.biopharma_dive · 3mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that